Enclomiphene Citrate Cost in Nevada 2026

What Enclomiphene Citrate Is and Why Nevada Pricing Is Complicated

Enclomiphene citrate is the trans-isomer of clomiphene and acts as a selective estrogen receptor antagonist at the hypothalamus, driving a rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that stimulates endogenous testosterone production [1]. Because it preserves sperm production while raising testosterone, it has become a first-line option for men with secondary hypogonadism who want to maintain fertility, a property that conventional testosterone replacement cannot match [2].

Pricing is complicated in Nevada for two distinct reasons. First, the branded product (Androxal) had a narrow commercial life before its manufacturer pulled it from the U.S. market, leaving compounded 503A formulations as the dominant supply channel. Second, off-label use for secondary hypogonadism means insurers categorize the drug differently depending on plan type, diagnosis codes submitted, and state mandate laws, none of which currently favor coverage in Nevada.

A 2021 analysis published in the Journal of Urology found that men with secondary hypogonadism who used clomiphene-class agents saw total serum testosterone rise from a mean of 232 ng/dL at baseline to 463 ng/dL at 3 months, with LH rising proportionally [3]. Enclomiphene's selectivity for the trans-isomer means fewer estrogenic side effects than racemic clomiphene, a point documented in the key Phase III data reviewed by the FDA [4].

The Actual Cash Price of Enclomiphene Citrate in Nevada in 2026

The cash price for compounded enclomiphene citrate at a 503A pharmacy serving Nevada patients runs approximately $90 per month for a 12.5 mg or 25 mg daily oral capsule in 2026. That price covers a 30-day supply and is consistent whether the prescription is written by an in-person provider or a telehealth clinician licensed in Nevada.

No brand-name retail product is commercially available in Nevada chain pharmacies in 2026. Because Androxal is no longer actively marketed, GoodRx and similar coupon tools show no usable price for enclomiphene at major retail chains like Walgreens or CVS in Las Vegas or Reno. Patients who call retail pharmacies and ask for "clomiphene" will be quoted racemic clomiphene (Clomid generics), which is a different compound [5].

The $90 monthly figure reflects the compounding pharmacy's ingredient cost, encapsulation, quality testing, and dispensing fee. Some 503A pharmacies bundle a quarterly supply for roughly $250 to $260, saving approximately $10 to $20 per month for men who commit to a 90-day trial. Shipping to a Nevada address from an out-of-state 503A pharmacy is legal provided the pharmacy holds a valid Nevada non-resident pharmacy license issued by the Nevada State Board of Pharmacy [6].

Kim et al. (BJU Int 2016, N=124) randomized men with secondary hypogonadism to enclomiphene or testosterone gel for 12 weeks and found that enclomiphene produced a statistically significant rise in serum testosterone (P<0.001) while preserving sperm concentration, whereas testosterone gel suppressed sperm counts [7]. That fertility-preservation data is part of why prescribers and patients accept an out-of-pocket cost that has no insurance offset.

Nevada Medicaid Coverage for Enclomiphene Citrate

Nevada Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The state's Medicaid preferred drug list classifies the drug as off-label for that indication, and no supplemental rebate agreement exists that would place it on a covered tier [8].

Nevada Medicaid (administered as the Nevada Check Up and Nevada Medicaid programs under the Division of Health Care Financing and Policy) follows a Pharmacy and Therapeutics committee review cycle. Enclomiphene has not cleared that cycle for male hypogonadism as of January 2026. Providers who submit a prior authorization request for enclomiphene under secondary hypogonadism will receive a denial citing the off-label status.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend against the routine use of testosterone therapy in men who are interested in maintaining or initiating fertility" and instead supports use of selective estrogen receptor modulators like clomiphene-class agents as an alternative [9]. Despite that guideline support, Medicaid programs are not obligated to cover drugs used off-label, and Nevada's program has not made an exception here.

Men enrolled in Nevada Medicaid who need enclomiphene will almost always pay cash. At $90 per month, the annual cost is $1,080, which is meaningful on a Medicaid-eligible income. The cheapest mitigation is a manufacturer or pharmacy savings program, discussed below.

Commercial Insurance Coverage in Nevada

Commercial insurers operating in Nevada, including plans sold through Nevada Health Link (the state ACA marketplace) and employer-sponsored plans, rarely cover enclomiphene citrate for male hypogonadism. The core obstacle is the off-label classification for secondary hypogonadism combined with the absence of a widely adopted ICD-10 code pathway that triggers automatic formulary coverage.

Blue Cross Blue Shield plans in Nevada, UnitedHealthcare, and Aetna all require prior authorization for any clomiphene-class agent prescribed to men. Appeals are possible but have a low approval rate because the insurer's clinical criteria typically require failure of an FDA-approved testosterone replacement product first, and enclomiphene's main clinical advantage is precisely that it avoids testosterone suppression of fertility [10].

A 2023 JAMA Internal Medicine perspective noted that insurance coverage gaps for male fertility-preserving hormone treatments create a two-tiered access system, where men with disposable income can access 503A compounded agents while lower-income men are pushed toward covered testosterone products that impair fertility [11]. That dynamic applies directly to Nevada's insurance market.

Men with HSA-eligible high-deductible health plans can pay for compounded enclomiphene using pre-tax HSA or FSA dollars, which effectively reduces the $90 monthly cost by their marginal tax rate. At a 22% federal bracket, the after-tax cost drops to roughly $70 per month.

Is Compounded Enclomiphene Citrate Legal in Nevada?

Compounded enclomiphene citrate is legal in Nevada when dispensed by a 503A pharmacy operating under a valid prescription for an identified patient. Nevada follows federal 503A compounding rules under the Drug Quality and Security Act of 2013 and adds oversight through the Nevada State Board of Pharmacy [6].

A 503A pharmacy may compound enclomiphene citrate because the active pharmaceutical ingredient (API) is commercially available from FDA-registered API suppliers, and the compound is prepared for a specific patient under a licensed prescriber's order. The pharmacy may not mass-produce enclomiphene for office stock (that would require 503B outsourcing facility registration) [12].

The FDA's guidance on compounding and the "essentially a copy" rule matters here. Because no commercially marketed enclomiphene product is currently available in the U.S. with an active NDA, 503A pharmacies are not prohibited from compounding it as an essentially-a-copy product. This is a nuance that distinguishes enclomiphene from, for example, semaglutide, where an FDA-approved product is on the market and the copy-rule applies more strictly [13].

Nevada prescribers, including telehealth physicians and nurse practitioners licensed in Nevada, may legally write a prescription for compounded enclomiphene citrate for a Nevada patient. The prescription must include the patient's name, the prescriber's DEA or NPI number, the compound's strength and quantity, and directions for use.

Telehealth Access to Enclomiphene Citrate in Nevada

Telehealth prescribing of enclomiphene citrate is fully permitted in Nevada in 2026. Nevada Revised Statutes Chapter 633 and the Nevada State Board of Medical Examiners allow physicians and osteopaths to prescribe Schedule-uncontrolled medications (enclomiphene is not a controlled substance) via telemedicine after establishing a valid provider-patient relationship [14].

A Nevada telehealth visit for enclomiphene typically follows this sequence. The patient completes an online intake with symptom history and prior lab work. The provider orders or reviews a serum total testosterone, LH, FSH, and sex hormone-binding globulin (SHBG) panel. If total testosterone is below approximately 300 ng/dL with inappropriately normal or low LH and FSH confirming secondary hypogonadism, the provider may prescribe enclomiphene [9]. The prescription is transmitted electronically to a 503A compounding pharmacy, and capsules are mailed to the patient's Nevada address.

HealthRX's clinical protocol requires a follow-up testosterone and LH panel at 6 to 8 weeks to confirm response before continuing therapy. Men who do not reach a testosterone level above 400 ng/dL on 25 mg daily at 8 weeks are evaluated for dose adjustment or a change in treatment strategy.

The entire workflow, from intake to pharmacy shipment, takes 3 to 5 business days in most Nevada markets, including Las Vegas, Henderson, Reno, Sparks, and rural counties served by telehealth.

How Enclomiphene Compares Clinically to Testosterone Replacement

Understanding cost in context means understanding what you are paying for. Enclomiphene citrate works differently from topical testosterone gels, injectable testosterone cypionate, or testosterone pellets. Where exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and can reduce sperm counts by 90% or more within weeks, enclomiphene stimulates the axis [7].

In the Kim et al. BJU Int 2016 trial (N=124), men on enclomiphene 12.5 mg or 25 mg daily for 12 weeks maintained sperm concentrations above 20 million/mL while testosterone rose significantly. Men on testosterone gel 1.62% saw testosterone normalize but sperm concentration fall below 15 million/mL in the majority of subjects [7]. This is the clinical basis for prescribing enclomiphene to men with secondary hypogonadism who have not yet completed their families.

A 2019 study in Fertility and Sterility (N=98) showed that clomiphene-class agents used in men with hypogonadotropic hypogonadism produced pregnancy rates of 40% at 12 months in couples with female partners who had no identifiable infertility factor [15]. Those data come from racemic clomiphene but are mechanistically applicable to enclomiphene given the shared receptor antagonism pathway.

Testosterone cypionate 200 mg every 2 weeks by injection costs as little as $30 to $40 per month with a GoodRx coupon at a Nevada pharmacy. Enclomiphene at $90 per month costs more. That price difference reflects the fertility-preservation benefit and the absence of hypothalamic-pituitary suppression, not a manufacturing premium. Men who do not need fertility preservation should discuss with their provider whether testosterone replacement is a more cost-effective choice for their situation.

Nevada-Specific Discount Programs and Cost-Reduction Strategies

Several strategies can reduce the out-of-pocket cost of enclomiphene citrate for Nevada patients.

Telehealth platforms, including HealthRX, sometimes bundle the provider visit cost with the pharmacy cost into a single monthly membership fee, which can reduce the all-in monthly expense compared with paying separately for a physician visit and a pharmacy fill. Membership pricing at telehealth men's health platforms in Nevada ranges from $99 to $149 per month inclusive of medication, lab oversight, and provider messaging.

Some 503A compounding pharmacies offer a loyalty or auto-refill discount of 10% to 15% for patients who enroll in automatic monthly shipments. On a $90 base price, a 10% discount saves $108 per year.

HSA and FSA accounts cover compounded prescription medications including enclomiphene. The IRS treats a licensed prescriber's compounded prescription the same as a branded drug for HSA-eligibility purposes [16]. A Nevada patient in the 22% federal bracket and 6.85% Nevada-adjacent income bracket (Nevada has no state income tax) saves approximately $26 per month in tax by paying through an HSA rather than post-tax dollars.

GoodRx and RxSaver do not currently list compounded enclomiphene because those platforms index retail pharmacies, not 503A compounders. Patients should not expect a GoodRx coupon to apply at a compounding pharmacy. Manufacturer coupons from the original Androxal brand are no longer active.

Nevada's Senior Rx program assists residents 62 and older with prescription drug costs, but it primarily covers drugs on the state Medicaid preferred drug list and is unlikely to help with off-label compounded enclomiphene [17].

Lab Testing Costs in Nevada That Accompany Enclomiphene Therapy

Enclomiphene therapy requires baseline and monitoring labs. The standard panel for initiating therapy includes serum total testosterone, LH, FSH, SHBG, estradiol, prolactin, and a complete metabolic panel. In Nevada, a direct-pay lab panel through Quest Diagnostics or LabCorp without insurance runs approximately $80 to $150 depending on the tests ordered.

Some telehealth platforms include lab costs in their monthly fee. Others require the patient to pay out of pocket at a patient service center. Quest Diagnostics has locations in Las Vegas (multiple), Henderson, North Las Vegas, Reno, and Sparks. LabCorp serves similar Nevada markets.

After the baseline panel, monitoring typically requires a testosterone and LH draw at 6 to 8 weeks and again at 3 months. Annual monitoring includes a hematocrit (polycythemia is less of a concern with enclomiphene than with exogenous testosterone, but the Endocrine Society recommends baseline and annual monitoring for any hormone therapy affecting erythropoiesis) [9].

If the treating provider has ordered labs through an insured patient's commercial plan, those labs may be covered under the patient's annual wellness or diagnostic benefit, even if the enclomiphene prescription itself is not covered. Patients should ask their insurer whether a testosterone panel submitted under ICD-10 code E29.1 (testicular hypofunction) is covered as a diagnostic lab.

Dosing Reference for Prescribers and Patients

The standard enclomiphene citrate starting dose for secondary hypogonadism in adult males is 12.5 mg orally once daily, titrated to 25 mg daily at 4 to 6 weeks if testosterone response is insufficient [4]. Both doses are available from Nevada 503A compounding pharmacies as oral capsules or tablets at the same $90 monthly price for a 30-day supply.

The drug is taken in the morning with or without food. No significant food interaction has been documented in Phase III trial data. Men with a BMI <40 and no active liver disease are generally appropriate candidates. Enclomiphene is contraindicated in individuals with a personal history of hormone-sensitive tumors, and prescribers should rule out primary hypogonadism (elevated LH and FSH with low testosterone) before prescribing, as enclomiphene cannot stimulate a non-functional testis [7].

Estradiol should be monitored because enclomiphene's stimulation of LH can increase intratesticular aromatization of testosterone to estradiol. If estradiol rises above 40 pg/mL with symptoms, prescribers may add a low-dose aromatase inhibitor or reduce the enclomiphene dose [9].

At 25 mg daily for 30 days, the total monthly API content per patient is 750 mg. A 503A pharmacy must source this from an FDA-registered bulk API supplier and document lot testing for identity, potency, and sterility before dispensing [12].